{"id":"experimental-peritoneal-dialysis-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Peritonitis"},{"rate":null,"effect":"Hyperglycemia (if glucose-based)"},{"rate":null,"effect":"Electrolyte imbalances"},{"rate":null,"effect":"Abdominal discomfort"}]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Peritoneal dialysis solutions facilitate the removal of uremic waste products and excess fluid across the peritoneal membrane. This experimental formulation likely incorporates novel osmotic agents, electrolyte compositions, or biocompatible additives to enhance dialysate performance and reduce peritoneal membrane injury compared to conventional solutions.","oneSentence":"An experimental peritoneal dialysis solution designed to improve solute clearance and fluid removal in patients with end-stage renal disease undergoing peritoneal dialysis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:11:59.348Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"End-stage renal disease requiring peritoneal dialysis"}]},"trialDetails":[{"nctId":"NCT03994471","phase":"PHASE3","title":"Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.","status":"RECRUITING","sponsor":"Iperboreal Pharma Srl","startDate":"2022-12-14","conditions":"End Stage Renal Disease","enrollment":170},{"nctId":"NCT07077538","phase":"NA","title":"Clinical Study of the Use of Amino Acid Peritoneal Dialysate in Diabetic Patients","status":"RECRUITING","sponsor":"The People's Hospital of Gaozhou","startDate":"2025-07-30","conditions":"Peritoneal Dialysis, Diabetes","enrollment":70},{"nctId":"NCT00214721","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of an Experimental Solution for Peritoneal Dialysis","status":"COMPLETED","sponsor":"Vantive Health LLC","startDate":"2005-02","conditions":"End Stage Renal Disease","enrollment":120},{"nctId":"NCT00214695","phase":"NA","title":"A Subjective Evaluation of Inflow Pain Associated With the Use of an Experimental Solution for Peritoneal Dialysis","status":"COMPLETED","sponsor":"Vantive Health LLC","startDate":"2005-05","conditions":"End Stage Renal Disease","enrollment":20},{"nctId":"NCT06597201","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.","status":"RECRUITING","sponsor":"Chengdu Qingshan Likang Pharmaceutical Co., Ltd","startDate":"2024-08-09","conditions":"End Stage Renal Disease (ESRD)","enrollment":400},{"nctId":"NCT06738550","phase":"NA","title":"Effect of Agave Inulin on Constipation and Quality of Life in Peritoneal Dialysis Patients.","status":"ENROLLING_BY_INVITATION","sponsor":"NIN Institute","startDate":"2023-03-01","conditions":"Constipation, Peritoneal Dialysis (PD), CKD","enrollment":45},{"nctId":"NCT06119373","phase":"NA","title":"Incremental PD With Single Icodextrin Exchange","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-12-01","conditions":"Peritoneal Dialysis Complication, Residual Kidney Function, Survival","enrollment":72},{"nctId":"NCT04001036","phase":"PHASE2","title":"Efficacy and Safety Assessments of a Peritoneal Dialysis Solution Containing Glucose, Xylitol, and L-Carnitine in CAPD","status":"TERMINATED","sponsor":"Iperboreal Pharma Srl","startDate":"2019-09-01","conditions":"End Stage Renal Disease","enrollment":11},{"nctId":"NCT02909153","phase":"PHASE1","title":"Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2017-01","conditions":"Peritoneal Dialysis (PD), Anemia, Chronic Kidney Disease","enrollment":30},{"nctId":"NCT01353638","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis","status":"TERMINATED","sponsor":"Christoph Aufricht","startDate":"2011-04","conditions":"End Stage Renal Disease","enrollment":25},{"nctId":"NCT01292863","phase":"NA","title":"The Impact of Delflex on Mesothelial Cell Viability and Peritoneal Transport","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2011-03","conditions":"End Stage Renal Disease","enrollment":""},{"nctId":"NCT00922701","phase":"PHASE2","title":"L-Carnitine in Peritoneal Dialysis","status":"COMPLETED","sponsor":"Iperboreal Pharma Srl","startDate":"2004-06","conditions":"End-Stage Renal Disease","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Experimental Peritoneal Dialysis Solution","genericName":"Experimental Peritoneal Dialysis Solution","companyName":"Vantive Health LLC","companyId":"vantive-health-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"An experimental peritoneal dialysis solution designed to improve solute clearance and fluid removal in patients with end-stage renal disease undergoing peritoneal dialysis. Used for End-stage renal disease requiring peritoneal dialysis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}